The effect of social support, depression, and illness perception on treatment adherence in patients with multiple sclerosis

Yıl 2022, , 323 - 329, 31.10.2022

Derya Gırgın Zeynep Tosun , Nilda Turgut Sibel Guler

https://doi.org/10.5472/marumj.1192560

Öz

Objective: This study was planned to determine the treatment adherence levels of multiple sclerosis (MS) patients and the factors
affecting treatment adherence.
Patients and Methods: This descriptive and cross-sectional study was conducted with 211 people with MS. Data for this study was
obtained through face-to-face interviews with MS patients who presented at the neurology outpatient clinics of two university
hospitals between April and October 2018. The “Morisky, Green, and Levine Adherence Scale”, “Beck Depression Inventory”,
“Multidimensional Perceived Social Support Scale”, and the “Illness Perception Scale” were used in data collection.
Results: The mean age of the sample was 40.03±10.82, and 70.1% were female. Treatment adherence was not good in half of the
patients (51.7%). Patients with good adherence were found to have higher Multidimensional Perceived Social Support Scale scores
(p<0.01) and lower Beck Depression Inventory scores (p<0.01). The illness perceptions of the patients regarding MS did not affect
treatment adherence (p>0.05).
Conclusion: Treatment adherence was insufficient in half of the MS patients. According to our findings, ensuring more cooperation
with the families of patients, which constitute the strongest source of social support, increasing treatment adherence can be suggested
as well as screening patients with regard to depressive symptomology during follow-up.

Anahtar Kelimeler

Multiple sclerosis, Treatment adherence, Social support, Depression, Illness perception

Kaynakça

• GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18:459-80. doi:10.1016/S1474-4422(18)30499-X
• Celik Y, Birgili O, Yılmaz H, et al. Prevalence of multiple sclerosis in the metropolitan area of Edirne City, Turkey. Balkan Med J 2011; 28:193-6 doi: 10.5174/tutfd.2010.04089.0
• Türk Börü Ü, Duman A, Kulualp AŞ, et al. Multiple sclerosis prevalence study: The comparison of 3 coastal cities, located in the black sea and mediterranean regions of Turkey. Medicine (Baltimore) 2018;97:e12856. doi:10.1097/MD.0000000000012856
• Akdemir N, Terzi M, Arslan N, Onar M. Prevalence of multiple sclerosis in the Middle Black Sea Region of Turkey and demographic characteristics of patients. Noro Psikiyatr Ars 2017;54:11-4. doi:10.5152/npa.2016.12451
• Gökçe ŞF, Çiğdem B, Nemmezi Karaca S, et al. Prevalence of multiple sclerosis in an urban population of Sivas province in Turkey. Turk J Med Sci 2019;49:288-94. doi:10.3906/sag-1808-112
• Magyari M, Sorensen PS. The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. Curr Opin Neurol 2019;32:320-26. doi:10.1097/WCO.0000000000000695
• McKay KA, Tremlett H, Patten SB, et al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler 2017;23:588-96. doi:10.1177/1352458516657440
• Hao J, Pitcavage J, Jones JB, Hoegerl C, Graham J. Measuring adherence and outcomes in the treatment of patients with multiple sclerosis. J Am Osteopath Assoc 2017;117:737-47. doi:10.7556/jaoa.2017.145
• Köşkderelioğlu A, Gedizlioğlu M, Ortan P, Öcek Ö. Evaluation of the adherence to immunmodulatory treatment in patients with multiple sclerosis. Noro Psikiyatr Ars 2015;52:376-9. doi:10.5152/npa.2015.8825
• Erbay Ö, Usta Yeşilbalkan Ö, Yüceyar N. Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis. J Neurosci Nurs 2018;50:291-7. doi:10.1097/JNN.0000000000000395
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74. doi:10.1097/00005650-198601000-00007
• Weinman J, Petrie K, Moss-Morris R, Horne R. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health 1996; 11:431-45. doi: 10.1080/08870449608400270
• Moss-Morris R, Weinman J, Petrie K, et al. The revised illness perception questionnaire (IPQ-R). Psychol Health 2002;17:1-16. doi:10.1080/08870440290001494
• Kocaman N, Ozkan M, Armay Z, Ozkan S. The reliability and the validity study of Turkish adaptation of the revised Illness Perception Questionnaire. Anatolian Journal of Psychiatry 2007; 8:271-280.
• Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support. J Pers Assess 1988; 52 :30-41. doi:10.1207/s15327752jpa5201_2
• Eker D, Arkar H. Perceived social support: psychometric properties of the MSPSS in normal and pathological groups in a developing country. Soc Psychiatry Psychiatr Epidemiol 1995;30:121-6. doi:10.1007/BF00802040
• Eker D, Arkar H, Yaldız H. Factorial structure, validity, and reliability of revised form of the Multidimensional Scale of Perceived Social Support. Türk Psikiyatri Dergisi 2001; 12: 17-25.
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71. doi:10.1001/archpsyc.1961.01710120031004
• Hisli N. Use of the Beck Depression Inventory with Turkish uni versity students: reliablity, validity and factor analysis. J Psychol1989;:3-13.
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherencet o disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77. doi:10.1111/j.1468-1331.2010.03110.x
• MorilloVerdugo R, Ramírez Herráiz E, Fernández-Del Olmo R, et al. Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Prefer Adherence 2019;13:261-72. doi:10.2147/PPA.S187983
• Câmara NAAC, Gondim APS. Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis. Braz J Pharm Sci 2017;53:e16132.doi.org/10.1590/s2175-97902017000116132
• Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9. doi:10.1191/1352458505ms1173oa
• Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm 2016;22:1394-401. doi:10.18553/jmcp.2016.22.12.1394
• Gromisch ES, Turner AP, Leipertz SL, et al. Who is not coming to clinic? A predictive model of excessive missed appointments in persons with multiple sclerosis. Mult Scler Relat Disord 2020;38:101513. doi:10.1016/j.msard.2019.101513
• Ožura A, Kovač L, Sega S. Adherence to disease-modifying the rapies and attitudes regarding disease in patients with multiple sclerosis. Clin Neurol Neurosurg 2013;115 Suppl1:S6-S11. doi:10.1016/j.clineuro.2013.09.013
• Kołtuniuk A, Rosińczuk J. The levels of depression, anxiety, acceptance of ıllness, and medication adherence in patients with multiple sclerosis –descriptive and correlational study. Int J Med Sci 2021;18:216-25. doi:10.7150/ijms.51172
• Zengin O, Erbay E, Yıldırım B, Altındag O. Quality of life, coping, and social support in patients with multiple sclerosis: A pilot study. Turk J Neurol 2017; 23:211-8.
• Kasser SL, Kosma M. Social cognitive factors, physical activity, and mobility ımpairment in adults with multiple sclerosis. Behav Med 2018;44:306-13. doi:10.1080/08964289.2017.1368441
• Soyuer F, Unalan D, Mirza M. Depressive symptoms in multiple sclerosis and the association with sociodemographic factors and functional status. Turk J Neurol 2010;16:31-5.
• Bilgi E, Ozdemir HH, Bulut S. Determining the frequency of depression and cognitive dysfunction in patients with multiple sclerosis. TJN 2013; 19:11-4.
• Gottberg K, Einarsson U, Fredrikson S, et al. A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry 2007;78:60-5. doi:10.1136/jnnp.2006.090654